TRENT LENGL: Open Payments
NPI 1144374232 · SPOKANE, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,477 in 89 payments from 14 companies in 2025. Trend: 2023 $1,498 · 2024 $2,028 · 2025 $1,477
Food & beverage: $1,405Education: $72
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 25 | $270 |
| Organon LLC | 13 | $246 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 9 | $197 |
| Janssen Biotech, Inc. | 9 | $169 |
| Amgen Inc. | 12 | $161 |
| Novartis Pharmaceuticals Corporation | 5 | $90 |
| Regeneron Healthcare Solutions, Inc. | 3 | $75 |
| UCB, Inc. | 2 | $56 |
| Galderma Laboratories, L.P. | 3 | $56 |
| Lilly USA, LLC | 2 | $43 |
Products named: SKYRIZI, VTAMA, TREMFYA, OTEZLA, ILUMYA, DUPIXENT, Bimzelx, EBGLYSS.
Industry payments across WA — which companies pay providers there.
